Jeffery W. Kelly
| Jeffery W. Kelly | |
|---|---|
| Born |
August 23, 1960 Medina, NY |
| Institutions | |
| Alma mater | |
Jeffery W. Kelly (born August 23, 1960 in Medina, New York) is the former Dean of Graduate Studies (2000-2008) and Vice President of Academic Affairs (2000-2006) and currently is the Chairman of Molecular Medicine and the Lita Annenberg Hazen Professor of Chemistry within the Skaggs Institute of Chemical Biology at The Scripps Research Institute in La Jolla, California. His research focuses on understanding protein folding, misfolding and aggregation and on developing both chemical and biological strategies to ameliorate diseases caused by protein misfolding and/or aggregation. Of the 100 Ph.D. students and postdoctoral fellows who have trained in the Kelly Lab., > 40 are in tenured or tenure-track academic jobs.
Kelly received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill (1986) and performed post-doctoral research at The Rockefeller University (1986–89). His research focuses on the chemistry and biology of protein homeostasis or proteostasis. Besides studying the structural and energetic basis underlying protein folding, his laboratory also studies the etiology of neurodegenerative diseases linked to protein aggregation, including Alzheimer's disease, Parkinson's Disease, and the light chain, gelsolin and transthyretin-based amyloidoses–publishing over 320 peer-reviewed papers in this area to date (h-index = > 85; ISI Web of Science). He has also provided insight into genetic diseases associated with loss of protein function, such as the lysosomal storage diseases.
Kelly has cofounded three biotechnology companies, FoldRx Pharmaceuticals (with Susan Lindquist), now owned by Pfizer, Proteostasis Therapeutics, Inc. (with Andrew Dillin and Richard Morimoto) (a NASDAQ public company) and Misfolding Diagnostics (with Xin Jiang and Justin Chapman; a private corporation). The Kelly laboratory discovered the first regulatory agency-approved drug that slows the progression of a human amyloid disease using a structure-based design approach. This drug, now called Tafamidis or Vyndaqel, slowed the progression of familial amyloid polyneuropathy in an 18-month placebo controlled trial and in a 12-month extension study sponsored by FoldRx Pharmaceuticals (acquired by Pfizer in 2010). Vyndaqel or Tafamidis was approved for the treatment of Familial amyloid Polyneuropathy by the European Medicines Agency in late 2011 and subsequently has been approved in > 30 countries. A second statistically significant clinical trial with the repurposed Merck Non steroidal anti-inflammatory drug, diflunisal discovered by Kelly to kinetically stabilize TTR, confirms the validity of the kinetic stabilizer mechanism to ameliorate the TTR amyloidoses. Collectively, the tafamidis and diflunisal data provide compelling pharmacologic evidence supporting the amyloid hypothesis, the idea that active transthyretin aggregation causes the loss of post-mitotic tissue in this degenerative amyloid disease. Moreover, these data validate transthyretin as a key drug target to stop the progression of several degenerative phenotypes linked to transthyretin aggregation.
...
Wikipedia